Recent sales of a little-known stock, Madrigal Pharmaceuticals (NASDAQ: MDGL), could bode well for Novo Nordisk A/S (NYSE: ...

Look no further than our top two stories of the year, and you’ll see that the GLP-1 craze and Big Pharma layoffs took center ...

Madrigal Pharmaceuticals, X4 Pharmaceuticals and Day One Biopharmaceuticals secured their maiden approvals this year in metabolic dysfunction-associated steatohepatitis, WHIM syndrome and pediatric ...

Smith covers the Healthcare sector, focusing on stocks such as Sagimet Biosciences, Inc. Class A, MoonLake Immunotherapeutics, and Madrigal Pharmaceuticals. Viking Therapeutics has an analyst ...

Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the thirteen ratings firms that are presently covering the ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Arcturus Therapeutics (ARCT – Research Report) ...

https://www.tipranks.com/news/the-fly/orthopediatrics-price-target-lowered-to-25-from-28-at-truist JMP Securities raised the firm’s price target on Madrigal ...

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), with a market capitalization of $6.66 billion, has positioned itself as a frontrunner in the treatment of nonalcoholic steatohepatitis (NASH ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), with a market capitalization of $6.66 billion, has positioned itself as a frontrunner in the treatment of nonalcoholic steatohepatitis (NASH) with its ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...